Related Experiment Videos
Brentuximab vedotin in Hodgkin's lymphoma
Barbara Pro1, Guilherme Fleury Perini
1Fox Chase Cancer Center, Philadelphia, PA, USA. barbara.pro@fccc.edu
Introduction:
Monoclonal antibodies (mAbs) directed against antigens expressed by tumor cells have become an effective therapeutic option in hematologic malignancies. Antibody-drug conjugates (ADC) utilize the targeting properties of mAbs to deliver cytotoxic agents inside the malignant cell. Brentuximab vedotin is a CD30-specific ADC with significant clinical activity in Hodgkin's lymphoma (HL).
Areas Covered:
CD30 is an ideal target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL). Early studies using unconjugated CD30 mAbs have demonstrated lack of objective responses in patients with recurrent cHL. Brentuximab vedotin is an ADC with significant clinical activity in patients with HL. Here, the authors review the biology of brentuximab vedotin, summarize available clinical data and discuss future treatment strategies.
Expert Opinion:
Brentuximab vedotin is a well-tolerated and highly active drug in patients with relapsed cHL. This novel agent has the potential to be incorporated in the standard management of the disease with significant therapeutic impact.
Related Concept Videos
Treatment Resistant Cancers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF